World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
74
Citations
28669
World Ranking
19290
National Ranking
9609

Arturo Molina publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Arturo Molina sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 310 publications — 19th percentile

19% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Arturo Molina D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Arturo Molina sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 74 D-Index — 4th percentile

4% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Arturo Molina is affiliated with Sutro Biopharma in the United States and has contributed extensively to the field of medicine, with a focus on genetics, hematology, molecular biology, oncology, and pathology and forensic medicine.

Their research work spans several areas including myeloproliferative neoplasms diagnosis and treatment, hemoglobinopathies and related disorders, acute myeloid leukemia research, chronic myeloid leukemia treatments, acute lymphoblastic leukemia research, lymphoma diagnosis and treatment, and macrophage migration inhibitory factor.

Frequent coauthors collaborating with Molina include Andrew Kuykendall, Sarita Khanna, Suneel Gupta, Naveen Pemmaraju, and Kristen Pettit, with collaboration counts ranging from 10 to 12 publications each.

Publications by Arturo Molina have appeared in various journals, with multiple papers featured in prominent venues such as Blood, the Journal of Clinical Oncology, Clinical Lymphoma Myeloma & Leukemia, Blood Advances, and Cancer Research.

Selected recent papers include:

  • "Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera", 2024, New England Journal of Medicine
  • "Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1-antibody-drug conjugate", 2022, Blood Advances
  • "Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemia", 2023, Blood Advances
  • "Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001", 2023, Oncotarget
  • "Phase 1 dose-escalation study of STRO-002, an antifolate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced, progressive platinum-resistant/refractory epithelial ovarian cancer (EOC).", 2021, Journal of Clinical Oncology

Best Publications

  • Abiraterone and Increased Survival in Metastatic Prostate Cancer

    Johann S. de Bono;Christopher J. Logothetis;Arturo Molina;Karim Fizazi

  • Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

    Charles J. Ryan;Matthew R. Smith;Johann S. De Bono;Arturo Molina

  • Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

    Karim Fizazi;Howard I. Scher;Arturo Molina;Christopher J. Logothetis

  • Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

    Charles J. Ryan;Matthew R. Smith;Karim Fizazi;Fred Saad

  • Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma

    Elise Olsen;Madeleine Duvic;Arthur Frankel;Youn Kim

  • Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer

    Gerhardt Attard;Alison H.M. Reid;Roger A'Hern;Christopher Parker

  • Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer

    Gerhardt Attard;Joost F. Swennenhuis;David Olmos;Alison H.M. Reid

  • Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer

    Daniel C. Danila;Michael J. Morris;Johann S. De Bono;Charles J. Ryan

  • Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate

    Alison H.M. Reid;Gerhardt Attard;Daniel C. Danila;Nikhil Babu Oommen

  • Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

    Koen Van Besien;Fausto R. Loberiza;Ruta Bajorunaite;James O. Armitage

  • Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer

    Howard I Scher;Glenn Heller;Arturo Molina;Gerhardt Attard

  • Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy

    Charles J. Ryan;Matthew R. Smith;Lawrence Fong;Jonathan E. Rosenberg

  • Solid Cancers After Bone Marrow Transplantation

    Smita Bhatia;Andrew D. Louie;Ravi Bhatia;Margaret R. O’Donnell

  • Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors.

    Amrita Krishnan;Smita Bhatia;Marilyn L. Slovak;Daniel A. Arber

  • Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)

    Dana E. Rathkopf;Matthew R. Smith;Johann S. De Bono;Christopher J. Logothetis

  • Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study

    Leo I. Gordon;Arturo Molina;Thomas Witzig;Christos Emmanouilides

  • Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.

    William Rastetter;Arturo Molina;Christine A White

  • Phase II Study of Abiraterone Acetate in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant With Serologic Response

    Charles J. Ryan;Shreya Shah;Eleni Efstathiou;Matthew R. Smith

  • Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial

    Christopher J Logothetis;Ethan Basch;Arturo Molina;Karim Fizazi

  • Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials

    Glenn Heller;Robert McCormack;Thian Kheoh;Arturo Molina

Frequent Co-Authors

Howard I. Scher
Howard I. Scher Memorial Sloan Kettering Cancer Center
Johann S. de Bono
Johann S. de Bono Institute of Cancer Research
Karim Fizazi
Karim Fizazi University of Paris-Saclay
Stephen J. Forman
Stephen J. Forman City Of Hope National Medical Center
Eric J. Small
Eric J. Small University of California, San Francisco
Matthew R. Smith
Matthew R. Smith Harvard University
Fred Saad
Fred Saad University of Montreal
Christopher J. Logothetis
Christopher J. Logothetis The University of Texas MD Anderson Cancer Center
Peter F.A. Mulders
Peter F.A. Mulders Radboud University
Leo I. Gordon
Leo I. Gordon Northwestern University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in medical studies, there are several online degree options and accelerated career pathways worth exploring. Online healthcare programs can offer greater flexibility and often allow for a faster route to professional practice.

Many nursing professionals are looking to advance their credentials efficiently. Accelerated DNP programs online are designed for experienced nurses seeking top-level roles, offering rigorous coursework that can be completed in less time than traditional programs.

If dissertation requirements are a concern, there are online DNP programs without dissertation that allow candidates to focus on clinical practice and leadership training instead of lengthy research projects.

Those aiming to enter the workforce more quickly may benefit from fast track LPN programs online, streamlining the path to becoming a Licensed Practical Nurse with curriculum designed for speed and accessibility.

For advanced practitioners, the fastest post master's PMHNP programs offer a direct route to becoming a Psychiatric Mental Health Nurse Practitioner, addressing a growing demand in mental health care.

Best Scientists Citing Arturo Molina

Trending Scientists

Recently Published Articles